Se-cure Pharmaceuticals Ltd. is a research-driven pharmaceutical company whose principal mission is the discovery, development of therapeutic solutions with an emphasis on safety of use through the identification and development of biochemical compositions working through a selective mechanism of action on the target tissues.

The company's vision centers on the development of therapeutic solutions that generate selective physiological responses with an emphasis on safety of use and the prevention of side effects following the long-term use. 

The first product Se-cure developed is in the field of Gynecology, marketed as Femarelle^®. Femarelle^® is a novel SERM for the management of menopause and osteoporosis. Femarelle^® exerts agonistic (stimulatory) activity on the estrogen receptors that control menopausal symptoms and the process of bone build-up, while having an antagonistic (blocking) effect on estrogen receptors in the breast and the uterus.

Currently Femarelle^® is marketed in over 12 countries. The partner alliance policy of Se-cure is targeting leading pharmaceutical companies in their respective country that are able to position Femarelle^® as the first line treatment for the management of menopause.

Se-cure’s pipeline consists of additional products in the fields of Urology (prostate) Dermatology (burns) and Dentistry (Guided Bone Regeneration).

Se-cure operates the most advanced pharmaceutical manufacturing facility from the production of the raw material to the packaging of the final product.

"The aspiration to perfect the development of a therapy means finding immediate relief, providing high efficacy, while minimizing future risks, and enabling safe long-term use."  

(Ron Gutterman, CEO)